Reported Saturday, FDA Advisory Committee Votes In Favor Of Bristol Myers Squibb's And 2seventy Bio's Abecma For Triple-Class Exposed Multiple Myeloma In Earlier Lines Of Therapy
Portfolio Pulse from Benzinga Newsdesk
The FDA Advisory Committee has voted in favor of Bristol Myers Squibb's and 2seventy Bio's Abecma for use in earlier lines of therapy for triple-class exposed multiple myeloma. The supplemental Biologics License Application for Abecma is still under review by the FDA. Abecma has already been approved in Japan and Switzerland and received a positive CHMP Opinion by the European Medicines Agency based on the KarMMa-3 study.
March 18, 2024 | 6:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's Abecma, developed in partnership with 2seventy Bio, receives positive vote from FDA Advisory Committee for expanded use in multiple myeloma treatment.
The positive vote from the FDA Advisory Committee for Abecma's expanded use in multiple myeloma treatment is a significant step towards final FDA approval. This development is likely to positively impact Bristol Myers Squibb's stock in the short term as it expands the potential market for Abecma and demonstrates the company's strong position in the biotech and healthcare sector.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
2seventy Bio's collaboration with Bristol Myers Squibb on Abecma receives favorable vote from FDA Advisory Committee for use in earlier lines of therapy for multiple myeloma.
The endorsement by the FDA Advisory Committee for the expanded use of Abecma, a product of the collaboration between 2seventy Bio and Bristol Myers Squibb, is likely to have a positive short-term impact on 2seventy Bio's stock. This approval process milestone not only validates the efficacy of Abecma in a broader treatment context but also highlights 2seventy Bio's capabilities and potential in the biotech industry.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90